Novel biomarkers like coronary calcium scores and body composition measures may help clinicians personalize diabetes treatment to reduce cardiovascular risk.
2-4xincreased cardiovascular disease risk in type 2 diabetes
What the researchers found
Imaging biomarkers (coronary calcium, cardiac/hepatic steatosis) and circulating biomarkers provide superior cardiovascular risk prediction in T2DM compared to traditional risk assessment tools.
Why it matters
Personalized treatment selection based on biomarkers could help ensure patients receive the diabetes medications most likely to protect their hearts and kidneys.
The numbers in context
No specific thresholds proposed; scoping review of imaging, circulating, and body composition biomarkers.
How the study worked
Scoping review of published literature on novel biomarkers for cardiovascular and renal risk stratification in type 2 diabetes.
Who was studied
Adults with type 2 diabetes
What this study cannot tell us
Scoping review format provides breadth but not the systematic rigor of a full meta-analysis; many biomarkers still need prospective validation in large clinical trials.
How to read the evidence
Scoping review synthesizing existing evidence; individual biomarker studies vary in design and quality.
When this study was published
Published in 2025, reflecting the latest understanding of biomarker-guided diabetes management.
The bigger picture
As GLP-1 receptor agonists and SGLT2 inhibitors prove their cardiovascular benefits, identifying which patients benefit most from each becomes critical for precision medicine in diabetes care.
Questions still open
- Which specific biomarker combinations offer the best predictive accuracy for treatment selection?
- Can biomarker-guided therapy selection improve hard cardiovascular outcomes versus standard care?
Common questions
What biomarkers can predict heart risk in diabetes?
How could biomarkers change diabetes treatment?
Read the original research
Can Clinical Biomarkers Guide Optimal Therapeutic Selection in Type 2 Diabetes Mellitus? A Scoping Review.
Current atherosclerosis reports, 27(1), 121
Citation
Quinaglia, Thiago; Silva, Gustavo L R; Matos-Souza, Jose Roberto; Coelho-Filho, Otavio Rizzi; Nadruz, Wilson; Sposito, Andrei C. (2025). Can Clinical Biomarkers Guide Optimal Therapeutic Selection in Type 2 Diabetes Mellitus? A Scoping Review.. Current atherosclerosis reports, 27(1), 121. https://doi.org/10.1007/s11883-025-01368-x